Cencora, Inc. to Issue Quarterly Dividend of $0.60 (NYSE:COR)

Posted by on Aug 6th, 2026

Cencora, Inc. (NYSE:COR – Get Free Report) announced a quarterly dividend on Wednesday, August 5th. Shareholders of record on Friday, August 14th will be given a dividend of 0.60 per share on Monday, August 31st. This represents a c) annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 14th.

Cencora has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 15 consecutive years. Cencora has a payout ratio of 13.9% meaning its dividend is sufficiently covered by earnings. Research analysts expect Cencora to earn $19.81 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 12.1%.

Cencora Trading Up 3.7%

NYSE COR opened at $317.68 on Thursday. The firm has a market cap of $61.81 billion, a PE ratio of 24.36, a price-to-earnings-growth ratio of 1.70 and a beta of 0.57. Cencora has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The stock has a 50-day moving average of $291.71 and a 200-day moving average of $314.58.

Cencora (NYSE:COR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion for the quarter, compared to analysts’ expectations of $84.31 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the business earned $4.00 earnings per share. As a group, sell-side analysts forecast that Cencora will post 17.79 EPS for the current year.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

  • Positive Sentiment: Quarterly earnings beat expectations. Adjusted diluted EPS rose 12% year over year to $4.48, ahead of the approximately $4.35–$4.37 consensus. Revenue increased 5.1% to $84.75 billion, also topping estimates. Cencora Reports Fiscal 2026 Third Quarter Results
  • Positive Sentiment: Cencora raised its fiscal 2026 adjusted EPS forecast to $17.75–$17.95 from $17.70–$17.90, signaling confidence in ongoing operating performance while maintaining its roughly $3 billion free-cash-flow target. The company kept its annual sales outlook unchanged. Cencora outlines fiscal 2026 EPS guidance
  • Positive Sentiment: Specialty pharmaceuticals drove growth. Management highlighted strength in U.S. Healthcare Solutions, specialty products, international operations and OneOncology, reinforcing the company’s strategy of expanding higher-value healthcare services. Cencora lifts annual profit view on specialty medicine demand
  • Positive Sentiment: Capital returns provided additional support. Cencora repurchased approximately $1 billion of stock during the quarter and declared a quarterly dividend of $0.60 per share, equivalent to an annualized yield of about 0.8% based on the provided stock data.
  • Neutral Sentiment: GLP-1 drug demand is a mixed factor. Growth in specialty medicines remains favorable, but a higher mix of lower-margin GLP-1 products is weighing on margins, potentially limiting the benefit of strong revenue growth. Cencora sees specialty growth while GLP-1 mix weighs on margins
  • Negative Sentiment: Regulatory uncertainty increased. The Federal Trade Commission is reportedly taking a closer look at Cencora’s proposed Covetrus animal-health merger, creating a potential timing or execution risk for the transaction. FTC reviews Cencora-Covetrus merger

Cencora Company Profile

(Get Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Recommended Stories

Dividend History for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.